Display options
Cite
Kingston B, Bailleux C, Delaloge S, et al. Exceptional Response to AKT Inhibition in Patients With Breast Cancer and Germline . JCO Precis Oncol. 2019;3doi: 10.1200/PO.19.00130.
Kingston, B., Bailleux, C., Delaloge, S., Schiavon, G., Scott, V., Lacroix-Triki, M., Carr, T. H., Kozarewa, I., Gevensleben, H., Kemp, Z., Pearson, A., Turner, N., & André, F. (2019). Exceptional Response to AKT Inhibition in Patients With Breast Cancer and Germline . JCO precision oncology, 3. https://doi.org/10.1200/PO.19.00130
Kingston, Belinda, et al. "Exceptional Response to AKT Inhibition in Patients With Breast Cancer and Germline ." JCO precision oncology vol. 3 (2019). doi: https://doi.org/10.1200/PO.19.00130
Kingston B, Bailleux C, Delaloge S, Schiavon G, Scott V, Lacroix-Triki M, Carr TH, Kozarewa I, Gevensleben H, Kemp Z, Pearson A, Turner N, André F. Exceptional Response to AKT Inhibition in Patients With Breast Cancer and Germline . JCO Precis Oncol. 2019 Dec 05;3. doi: 10.1200/PO.19.00130. eCollection 2019. PMID: 32923864; PMCID: PMC7446515.
Copy Download .nbib Format: NLM
Share it on

JCO Precis Oncol. 2019 Dec 05;3. doi: 10.1200/PO.19.00130. eCollection 2019.

Exceptional Response to AKT Inhibition in Patients With Breast Cancer and Germline .

JCO precision oncology

Belinda Kingston, Caroline Bailleux, Suzette Delaloge, Gaia Schiavon, Veronique Scott, Magali Lacroix-Triki, T Hedley Carr, Iwanka Kozarewa, Heidrun Gevensleben, Zoe Kemp, Alex Pearson, Nicholas Turner, Fabrice André

Affiliations

  1. Institute of Cancer Research, London, United Kingdom.
  2. Institut Gustave Roussy, Villejuif, France.
  3. AstraZeneca, IMED Oncology, Cambridge, United Kingdom.
  4. Bonn University Hospital, Bonn, Germany.
  5. The Royal Marsden NHS Foundation Trust, London, United Kingdom.

PMID: 32923864 PMCID: PMC7446515 DOI: 10.1200/PO.19.00130

[No abstract available.]

Conflict of interest statement

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I

References

  1. J Med Genet. 2000 Nov;37(11):828-30 - PubMed
  2. Int J Cancer. 2013 Jul 15;133(2):323-34 - PubMed
  3. Cancer Res. 2008 Sep 1;68(17):7066-72 - PubMed
  4. Nat Rev Cancer. 2001 Nov;1(2):157-62 - PubMed
  5. J Clin Oncol. 2017 Jul 10;35(20):2251-2259 - PubMed
  6. Ann Oncol. 2016 Oct;27(10):1928-40 - PubMed
  7. Mol Cancer Ther. 2015 Nov;14(11):2441-51 - PubMed
  8. Nat Rev Mol Cell Biol. 2012 Apr 04;13(5):283-96 - PubMed
  9. Nat Rev Mol Cell Biol. 2018 Sep;19(9):547-562 - PubMed
  10. Pediatr Blood Cancer. 2011 Aug;57(2):321-3 - PubMed
  11. Cancer Chemother Pharmacol. 2016 Apr;77(4):787-95 - PubMed
  12. Onco Targets Ther. 2016 Sep 12;9:5643-50 - PubMed
  13. Clin Cancer Res. 2018 May 1;24(9):2050-2059 - PubMed
  14. Clin Cancer Res. 2012 Jan 15;18(2):400-7 - PubMed
  15. Tumour Biol. 2016 Nov;37(11):14831-14839 - PubMed
  16. Oncol Lett. 2013 Jul;6(1):161-168 - PubMed
  17. Nat Genet. 2010 May;42(5):454-8 - PubMed
  18. Oncogene. 2005 Nov 14;24(50):7455-64 - PubMed
  19. Pediatr Res. 2014 Apr;75(4):527-34 - PubMed
  20. Discov Med. 2015 Feb;19(103):109-16 - PubMed
  21. PLoS One. 2015 Oct 15;10(10):e0140479 - PubMed
  22. Nat Clin Pract Oncol. 2008 Jun;5(6):357-61 - PubMed
  23. Cancer Res. 2009 May 15;69(10):4192-201 - PubMed
  24. Cell. 2014 Apr 24;157(3):595-610 - PubMed
  25. Lancet Oncol. 2017 Oct;18(10):1360-1372 - PubMed

Publication Types